Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1155/week)
    • Manufacturing(555/week)
    • Technology(1085/week)
    • Energy(397/week)
    • Other Manufacturing(315/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Upadacitinib

Jun 18, 2020
RINVOQ(TM) (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
Jun 06, 2020
AbbVie Presents Data Showing RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
Jun 04, 2020
New Long-term Data from RINVOQ(TM) (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Jun 01, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
May 27, 2020
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
Feb 05, 2020
RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Dec 18, 2019
AbbVie Receives European Commission Approval of RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Oct 31, 2019
RINVOQ(TM) (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Oct 18, 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Aug 27, 2019
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis
Aug 16, 2019
AbbVie Receives FDA Approval of RINVOQ(TM) (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
Jun 12, 2019
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
May 21, 2019
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
Feb 25, 2019
FDA responds to safety signal reported in required postmarketing trial for Xeljanz
Feb 19, 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Dec 20, 2018
AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Oct 23, 2018
AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
Oct 22, 2018
Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis
Oct 16, 2018
AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
Oct 08, 2018
AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
  •  
  • Page 1
  • ››

Latest News

Jun 11, 2025

Sherritt Reports Shareholder Meeting Results, Board Appointments and Committee Updates

Jun 11, 2025

Voyager Announces Pricing of Initial Public Offering

Jun 11, 2025

H&P To Participate in J.P. Morgan 2025 Energy, Power and Renewables Conference

Jun 11, 2025

CACI President and CEO John Mengucci Named ‘Executive of the Year’ by ACG National Capital

Jun 11, 2025

Atlas Announces Timing of Second Quarter 2025 Earnings Release and Conference Call

Jun 11, 2025

Kaiser Aluminum Corporation Announces Appointment of Glenda J. Minor to its Board of Directors

Jun 11, 2025

The SEER Group Expands Northwest Presence With Acquisition of Oregon’s Associated Heating & Air...

Jun 11, 2025

Phillips 66 to Speak at the J.P. Morgan 2025 Energy, Power, Renewables & Mining Conference

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia